key: cord-0946444-1a5saiho
authors: Hu, Z.; Ge, Q.; Luo, L.; Xu, T.; Zhang, K.; Lu, H. H.; Lin, W.; Boerwinkle, E.; Jin, L.; Xiong, M.
title: Population Vaccine Effectiveness and its Implication for Control of the Spread of COVID-19 in the US
date: 2021-05-05
journal: nan
DOI: 10.1101/2021.04.30.21256228
sha: 37d66c824ac4d9f6308c27f9a15427fdd1570a03
doc_id: 946444
cord_uid: 1a5saiho

Realized vaccine efficacy in population is highly different from the individual vaccine efficacy measured in clinical trial. The realized vaccine efficacy in population is substantially affected by the vaccine age-stratified prioritization strategy, population age-structure, non-pharmaceutical intervention (NPI). We proposed a population vaccine efficacy which integrated individual vaccine efficacy, vaccine prioritization strategy and NPI to measure and monitor the control of the spread of COVID-19. We found that 11 states in the US had low population vaccine efficacy and 20 states had high population efficacy. We demonstrated that although the proportion of the population who received at least one dose of COVID-19 vaccine across 11 low population vaccine efficacy states, in general, was greater than that in 20 high population vaccine efficacy states, the 11 low population vaccine efficacy states experienced the recent COVID-19 surge, while the number of new cases in the 20 high population vaccine efficacy states exponentially decreased. We demonstrated that the proportions of adults in the population across 50 states were significantly associated with the forecasted ending date of the COVID-19. We show that it was recent low proportion of adults vaccinated in Michigan that caused its COVID-19 surge. Using population vaccination efficacy, we forecasted that the earliest COVID-19 ending states were Hawaii, Arizona, Arkansas, and California (in the end of June, 2021) and the last COVID-19 ending states were Colorado, New York and Michigan (in the Spring, 2022).

There is increasing hope for ending the spread of COVI-19 and returning normal through vaccination. On April 2, 2021, CDC reported that Pfizer-BioNtech and Moderna vaccines had 80% effectiveness against SARS-2 infection after first dose and 90% effectiveness after second dose (1) . These vaccines were designed for the origin of SARS-CoV-2 virus. Unfortunately, mutations and natural selection generate new variants that increase virus replication, transmission, and escape of the immune system. There are three major rapidly circulating new variants: B.1.1.7 (that was initially reported in the United Kingdom on December 14, 2020), 501YV2 (B.1.351) (that was first announced in South Africa on December 18, 2020) and P.1(that was first described in Brazil on January 12, 2021), which reduce antibody neutralization and vaccine efficacy (2, 3) . These new variants raise concerns for increased transmission and escape from both vaccine and natural infection immunity.

It was reported that the Michigan coronavirus surged again. On April 6, 2021, the number of new cases in Michigan reached 6.041. However, on the same day, the total number of residents vaccinated was 3,054,258 and the coverage reached 37.7% (4). It was discovered that 40% of to correctly answer this question is vaccine distribution and dose prioritization plan design to increase population immunity levels against new variants. We identified the vaccine age distribution, which in turn caused the rapid transmission of B.1.1.7 variant in young population, was the major factor that led to the surge of Michigan coronavirus, using vaccine roll out real . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.04.30.21256228 doi: medRxiv preprint data and causal analysis. We developed a real data-based population vaccine efficacy index that took vaccine and non-pharmaceutical intervention (NPI) into account. We employ real-time COVID-19 transmission dynamic forecasting model and population vaccine efficacy index to design vaccine distribution curve and calculate the times when the COVD19 pandemic will end under the vaccine distribution plan for each state using the COVID-19 vaccination and new case data from January 12, 2021 to April 14, 2021, downloaded from https://ourworldindata.org/covid-vaccinations and https://coronavirus.jhu.edu/MAP.HTML.

Age-stratified vaccine distribution and prioritizing strategy were a major factor that caused the Michigan coronavirus surge again. To illustrate this, we presented is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2021. ; of vaccination in Texas increased. All ߙ coefficients in 50 states were listed in Table 2 will be stopped in the US. The earliest ending day of COVID-19 will be 6/24, 2021 in Hawaii (6/24, 2021, the number of new cases will be reduced to 4 and 75% of population will be vaccinated), Arizona (6/25, 2021, the number of new cases will be reduced to 22 and 69% of population will be vaccinated), Arkansas (6/25, 2021, the number of new cases will be reduced to 9, 66% of population will be vaccinated) and California (6/27/2021, the number of new cases . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.04.30.21256228 doi: medRxiv preprint will be reduced to 120, 80% of population will be vaccinated). The last ending day will be 3/28, 2022 in Colorado (the number of new cases will be reduced to 17, 80% of population will be vaccinated), 3/2, 2022 in New York (the number of new cases will be reduced to 59, 80% of population will be vaccinated) and 1/14, 2022 in Michigan (the number of new cases will be reduced to 30, 80% of population will be vaccinated). By the end of august, 2021, majority of states (33 states) will almost stop the spread of COVID-19. By the end of this year, 46 states will contain the transmission of COVID-19. By the spring, 2022, all states and regions in the US will contain COVID-19, our life will go to normal. and West Virginia. We also compared the proportions of adults (age 19-64) in these two groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Kendall correlation test showed that the proportion of adults in the state was significantly associated with the ending day of COVID-19 in the state (P-value < 0.00678).

The results for the vaccine distribution plans 2 and 3 were summarized in Table S1 and Figures S2, S3. Vaccine distribution plan 2 has some improvement on stopping transmission of COVID-19. The earliest ending states of COVID-19 will be Hawaii (5/27, 2021, the number of new cases will be reduced to 10, the proportion of vaccination will be 75.84%), District of Columbia (6/13, 2021, the number of new cases will be reduced to 10, the proportion of vaccination will be 76.83%), Arkansas (6/23. 2021, the number of new cases will be reduced to 10, the proportion of vaccination will be 64.56%), and Arizona (6/25, the number of new cases will be reduced to 22, the proportion of vaccination will be 68.76%). The last ending states under plan 2 will be New Jersey (4/7, 2022, the number of new cases will be 27, the proportion of vaccination will be 80%), Colorado (3/30, 2022, the number of new cases will be reduced to 17, the proportion of vaccination will be 80%) and New York (3/4, 2022, the number of new cases will be reduced to 58, the proportion of vaccination will be 80%). 

This study addressed several important issues in vaccination. We found that the agestructure of vaccine prioritization was an important factor that caused recent COVID-19 surge in Michigan. We compared the vaccine prioritization strategies for SARS-CoV-2 between Michigan and Texas and found that the proportion of vaccination in age group (16-49) in Michigan was much lower than that in Texas. We demonstrated by formal statistical test that difference in vaccination age-structure between Michigan and Texas was highly significant. It is less proportion of adults vaccinated in Michigan that caused its COVID-19 surge. The causal test also showed that the new virus variants were not a significant cause factor of the recent COVID-19 surge in Michigan. To further investigate the impact of age-structure on the spread of COVID-19, we compared the population age-structure across the 50 states in the US. We found that on the average, the proportion of adults in 11 low population vaccine efficacy states that experienced recent rises of COVID-19 were higher than that in 20 high population vaccine efficacy states with the recent decline of COVID-19. We showed that the proportions of the adults in the population was significantly associated with the ending date of COVID-19 in 50 states. The age structure may play an important role in the spread of COVID-19.

The efficacy of individual vaccine may not measure the real effect of vaccine in the population level. The vaccine prioritization strategies had a big impact on shaping local transmission dynamics. Also, the NPI plays a role in blocking the spread of COVID-19. The transmission dynamics of the COVID-19 is affected by the interplay between the NPI and vaccination. We . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. year, we may expect that the life in the US will return to normal.

None to declare

Z. Hu, data analysis Q. Ge, data analysis L.Luo, Data analysis T.Xu, data analysis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. 

Many thanks to the Texas Advanced Computing Center for computation support.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ;

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ;

1 5 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.04.30.21256228 doi: medRxiv preprint Figure S5 . Population vaccine efficacy map where the states in green color, denoted their population vaccine efficacy larger than 0.3, the states in red color denoted their population vaccine efficacy smaller than 0.13 and with non-negative exponential growth parameter ߛ , and the remaining states were in yellow color.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.04.30.21256228 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2021. ;

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight U.S. Locations

The emerging plasticity of SARS-CoV-2

New SARS-CoV-2 Variants -clinical, public health, and vaccine Implications